TD Cowen Rates Revolution Medicines (RVMD) Buy, $250 Price Target

On October 21, 2026, TD Cowen reaffirmed its positive stance on Revolution Medicines, Inc. (NASDAQ:RVMD), keeping a Buy rating and a $250.00 price target on the biotech firm. The research note underscores the firm's forward-looking confidence in the company's precision oncology pipeline as it develops targeted therapies for RAS-addicted cancers.

RVMD Revolution Medicines, Inc.

$182.15 ▲ +130.51% year to date

1M 3M YTD

Daily close · Oct 19, 2026

TD Cowen's Call on Revolution Medicines

In its research note published on October 21, 2026, TD Cowen maintained a Buy rating on Revolution Medicines with a price target of $250.00. The firm's outlook centers on the company's ongoing clinical developments in RAS(ON) inhibitors and companion treatments designed to target hard-to-treat cancer mutations.

Other Institutional Activity in Revolution Medicines

Large financial institutions have actively adjusted their holdings in Revolution Medicines during recent periods. Farallon Capital Management LLC reduced its stake by 54,421 shares, ending the period with 13,550,796 shares valued at about $2.66 billion. Baker Bros. Advisors, LP grew its holdings by 1,888,116 shares, ending with 11,443,357 shares worth about $2.25 billion. Jupiter Topco LLC increased its position by 5,368,072 shares to hold 10,736,145 shares valued at roughly $2.11 billion. Darwin Global Management, Ltd. lifted its stake by 8,418,823 shares, finishing with 10,629,822 shares worth about $2.09 billion. Nextech Invest, Ltd. kept its holdings unchanged at 7,601,087 shares valued at roughly $1.49 billion.

Revolution Medicines, Inc. Stock Down 0.1%

Revolution Medicines shares recently traded around $196.45 as of October 21, 2026, sitting close to its event-day close of $196.65. The stock trades above its 200-day moving average of $152.72 while sitting below its 50-day moving average of $202.45. The company carries a market capitalization of roughly $42.15 billion and a 52-week trading range spanning from a low of $52.48 to a high of $224.31.

Recent Earnings

Revolution Medicines reported a trailing twelve-month loss with an earnings per share of -$8.87. The company's return on equity sits at -79.1%, while its net margin reads at 0.0%. The company maintains a strong liquidity profile with a current ratio of 11.38 and a quick ratio of 11.12. The next earnings update is scheduled for November 4, 2026.

Insider Buying and Selling at Revolution Medicines, Inc.

Company insiders have completed several transactions in recent weeks. Director Elizabeth M. Anderson disposed of 10,143 shares on September 22, 2026, valued at approximately $1.96 million. General Counsel Jeffrey Todd Cislini sold 765 shares on September 25, 2026, at an average price of $207.32 for a total value of $158,600. Officer Anthony Mancini sold 3,708 shares on September 25, 2026, worth about $743,285. Officer Alan B. Sandler parted with 6,309 shares on September 29, 2026, valued at approximately $1.28 million.

Analysts Set New Price Targets

Wall Street firms remain active with coverage on the stock. On October 14, 2026, RBC Capital maintained an Outperform rating while raising its target from $259.00 to $260.00. Needham reiterated a Buy rating with a $275.00 target on October 15, 2026. William Blair initiated coverage with an Outperform rating on October 16, 2026. Truist Securities maintained a Buy rating on October 19, 2026, lifting its target from $240.00 to $241.00. Overall, the stock carries a strong buy consensus drawn from 24 analyst opinions with a mean target price of $257.84.

About Revolution Medicines

Headquartered in Redwood City, California, Revolution Medicines is a clinical-stage precision oncology company focused on developing novel therapies for patients with RAS-addicted cancers. The company builds a robust pipeline of RAS(ON) and RAS companion inhibitors designed to suppress cooperating survival pathways in tumor cells.

Bottom Line

Investors will watch the company's upcoming earnings report on November 4, 2026, for further updates on its clinical trial milestones and pipeline progress.